The anti-PD-L1 completely human IgG1 avelumab mediates ADCC17 as well as the haNK cells express the high affinity CD16, which enhances ADCC activity
The anti-PD-L1 completely human IgG1 avelumab mediates ADCC17 as well as the haNK cells express the high affinity CD16, which enhances ADCC activity.25 Avelumab has demonstrated (Glp1)-Apelin-13 clinical benefit in a variety of human tumor types. in tumor cell lysis. Studies show that while NK cells be capable of lyse haNK or aNK cells, the… Read More: The anti-PD-L1 completely human IgG1 avelumab mediates ADCC17 as well… »